Tags

Type your tag names separated by a space and hit enter

A randomized double-blind clinical trial with two different doses of arginine enhanced enteral nutrition in postsurgical cancer patients.
Eur Rev Med Pharmacol Sci 2010; 14(11):941-5ER

Abstract

OBJECTIVES

Patients with head and neck cancer undergoing surgery have a high incidence of postoperative complications. The aim of our study was to investigate whether postoperative nutrition of head and neck cancer patients, using an enteral high dose of arginine (20 g per day) vs a medium dose (12.3 g per day) could improve nutritional variables as well as clinical outcome.

MATERIAL AND METHODS

A population of 115 patients with oral and laryngeal cancer was enrolled. At surgery patients were randomly allocated to two groups: group I (58 patients) received an enteral diet supplements with a high dose of arginine (20 g per day) and group II (57 patients) received an isocaloric, isonitrogenous enteral formula with a medium dose of arginine (12.3 g per day).

RESULTS

Gastrointestinal tolerance (diarrhea) of both formulas was good (3.44% group I and 3.51% group II: ns). The postoperative infections complications were similar in both groups (8.6% group I and 12.2% group II: ns). Fistula was less frequent in enriched nutrition group (3.4% group I and 10.5% group II: p = 0.006). The length of postoperative stay was similar in both groups (27.2 +/- 17.8 days in group I vs 25.7 +/- 18.8 days in group II: ns).

CONCLUSIONS

Enriched arginine formula improves fistula wound complications in postoperative head and neck cancer patients. Our results suggest that these patients could benefit from a high dose of arginine enhanced enteral formula.

Authors+Show Affiliations

Institute of Endocrinology and Nutrition, Medicine School and Hospital Rio Hortega, University of Valladolid, Valladolid, Spain. dadluis@yahoo.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21284343

Citation

De Luis, D A., et al. "A Randomized Double-blind Clinical Trial With Two Different Doses of Arginine Enhanced Enteral Nutrition in Postsurgical Cancer Patients." European Review for Medical and Pharmacological Sciences, vol. 14, no. 11, 2010, pp. 941-5.
De Luis DA, Izaola O, Cuellar L, et al. A randomized double-blind clinical trial with two different doses of arginine enhanced enteral nutrition in postsurgical cancer patients. Eur Rev Med Pharmacol Sci. 2010;14(11):941-5.
De Luis, D. A., Izaola, O., Cuellar, L., Terroba, M. C., Martin, T., & Ventosa, M. (2010). A randomized double-blind clinical trial with two different doses of arginine enhanced enteral nutrition in postsurgical cancer patients. European Review for Medical and Pharmacological Sciences, 14(11), pp. 941-5.
De Luis DA, et al. A Randomized Double-blind Clinical Trial With Two Different Doses of Arginine Enhanced Enteral Nutrition in Postsurgical Cancer Patients. Eur Rev Med Pharmacol Sci. 2010;14(11):941-5. PubMed PMID: 21284343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized double-blind clinical trial with two different doses of arginine enhanced enteral nutrition in postsurgical cancer patients. AU - De Luis,D A, AU - Izaola,O, AU - Cuellar,L, AU - Terroba,M C, AU - Martin,T, AU - Ventosa,M, PY - 2011/2/3/entrez PY - 2011/2/3/pubmed PY - 2011/2/25/medline SP - 941 EP - 5 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 14 IS - 11 N2 - OBJECTIVES: Patients with head and neck cancer undergoing surgery have a high incidence of postoperative complications. The aim of our study was to investigate whether postoperative nutrition of head and neck cancer patients, using an enteral high dose of arginine (20 g per day) vs a medium dose (12.3 g per day) could improve nutritional variables as well as clinical outcome. MATERIAL AND METHODS: A population of 115 patients with oral and laryngeal cancer was enrolled. At surgery patients were randomly allocated to two groups: group I (58 patients) received an enteral diet supplements with a high dose of arginine (20 g per day) and group II (57 patients) received an isocaloric, isonitrogenous enteral formula with a medium dose of arginine (12.3 g per day). RESULTS: Gastrointestinal tolerance (diarrhea) of both formulas was good (3.44% group I and 3.51% group II: ns). The postoperative infections complications were similar in both groups (8.6% group I and 12.2% group II: ns). Fistula was less frequent in enriched nutrition group (3.4% group I and 10.5% group II: p = 0.006). The length of postoperative stay was similar in both groups (27.2 +/- 17.8 days in group I vs 25.7 +/- 18.8 days in group II: ns). CONCLUSIONS: Enriched arginine formula improves fistula wound complications in postoperative head and neck cancer patients. Our results suggest that these patients could benefit from a high dose of arginine enhanced enteral formula. SN - 1128-3602 UR - https://www.unboundmedicine.com/medline/citation/21284343/A_randomized_double_blind_clinical_trial_with_two_different_doses_of_arginine_enhanced_enteral_nutrition_in_postsurgical_cancer_patients_ L2 - https://medlineplus.gov/headandneckcancer.html DB - PRIME DP - Unbound Medicine ER -